Published • loading... • Updated
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
Investors allege ARS misled them about Neffy insurance coverage timing, and Rosen Law Firm says shareholders may recover losses without upfront fees.
- On Tuesday, Sept. 1, 2026, The Rosen Law Firm announced a securities class action lawsuit against ARS Pharmaceuticals, Inc. , with investors having until October 5, 2026, to move the Court to serve as lead plaintiff.
- According to the complaint, defendants allegedly provided overly positive statements regarding neffy's expected coverage timeline with CVS Caremark while concealing material adverse facts, causing shareholders to purchase ARS securities at artificially inflated prices.
- Bronstein, Gewirtz & Grossman, LLC also filed a class action against ARS and certain officers, alleging their statements regarding the Company's business prospects lacked a reasonable basis during the Class Period.
- Investors who purchased shares between March 9, 2026, and June 24, 2026, may be entitled to compensation without out-of-pocket costs via contingency fee arrangements; class members need not serve as lead plaintiff to share in any recovery.
- The Rosen Law Firm, which has recovered over $438 million for investors, represents clients in securities class actions globally; interested parties can contact Phillip Kim, Esq., toll-free at 866-767-3653 to review the complaint.
Insights by Ground AI
12 Articles
12 Articles
stonecountyenterprise.com+10 Reposted by 10 other sources
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
NEW YORK, Sept. 1, 2026 /PRNewswire/ -
·Wiggins, United States
Read Full Article
Coverage Details
Total News Sources12
Leaning Left0Leaning Right3Center8Last UpdatedBias Distribution73% Center
Bias Distribution
- 73% of the sources are Center
73% Center
C 73%
R 27%
Factuality
To view factuality data please Upgrade to Premium
